JP2022521119A5 - - Google Patents
Info
- Publication number
- JP2022521119A5 JP2022521119A5 JP2021532911A JP2021532911A JP2022521119A5 JP 2022521119 A5 JP2022521119 A5 JP 2022521119A5 JP 2021532911 A JP2021532911 A JP 2021532911A JP 2021532911 A JP2021532911 A JP 2021532911A JP 2022521119 A5 JP2022521119 A5 JP 2022521119A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- formula
- administered
- base
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024158993A JP2024175025A (ja) | 2019-01-30 | 2024-09-13 | 組織の灌流の増加における使用のためのイノシトールリン酸化合物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19382061 | 2019-01-30 | ||
| EP19382061.0 | 2019-01-30 | ||
| US201962913259P | 2019-10-10 | 2019-10-10 | |
| US62/913,259 | 2019-10-10 | ||
| PCT/ES2020/070070 WO2020157362A1 (en) | 2019-01-30 | 2020-01-30 | Inositol phosphate compounds for use in increasing tissular perfusion |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024158993A Division JP2024175025A (ja) | 2019-01-30 | 2024-09-13 | 組織の灌流の増加における使用のためのイノシトールリン酸化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022521119A JP2022521119A (ja) | 2022-04-06 |
| JP2022521119A5 true JP2022521119A5 (enExample) | 2022-09-14 |
Family
ID=69770927
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021532911A Pending JP2022521119A (ja) | 2019-01-30 | 2020-01-30 | 組織の灌流の増加における使用のためのイノシトールリン酸化合物 |
| JP2024158993A Pending JP2024175025A (ja) | 2019-01-30 | 2024-09-13 | 組織の灌流の増加における使用のためのイノシトールリン酸化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024158993A Pending JP2024175025A (ja) | 2019-01-30 | 2024-09-13 | 組織の灌流の増加における使用のためのイノシトールリン酸化合物 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20220000889A1 (enExample) |
| EP (1) | EP3917535A1 (enExample) |
| JP (2) | JP2022521119A (enExample) |
| KR (1) | KR20210148078A (enExample) |
| CN (1) | CN113365636A (enExample) |
| AU (1) | AU2020213713B2 (enExample) |
| BR (1) | BR112021014897A2 (enExample) |
| CA (1) | CA3130735A1 (enExample) |
| IL (1) | IL285084A (enExample) |
| MX (1) | MX2021008966A (enExample) |
| WO (1) | WO2020157362A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3113377A1 (en) | 2018-10-11 | 2020-04-16 | Sanifit Therapeutics S.A. | Inositol phosphates for the treatment of ectopic calcification |
| AU2021380963A1 (en) * | 2020-11-20 | 2023-06-22 | ETH Zürich | Inositol hexakisphosphate analogues for treatment of calcification associated kidney diseases |
| WO2024047037A1 (en) | 2022-08-30 | 2024-03-07 | ETH Zürich | Compositions for parenteral sustained release delivery of hydrophilic drugs |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5007790A (en) | 1989-04-11 | 1991-04-16 | Depomed Systems, Inc. | Sustained-release oral drug dosage form |
| ES2124303T3 (es) | 1992-03-25 | 1999-02-01 | Depomed Inc | Formas de dosificacion de farmacos orales de liberacion retardada a base de hidroxietilcelulosa. |
| US5582837A (en) | 1992-03-25 | 1996-12-10 | Depomed, Inc. | Alkyl-substituted cellulose-based sustained-release oral drug dosage forms |
| AU3290397A (en) | 1996-06-10 | 1998-01-07 | Depomed, Inc. | Gastric-retentive oral controlled drug delivery system with enhanced retention properties |
| US5972389A (en) | 1996-09-19 | 1999-10-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
| US6635280B2 (en) | 1997-06-06 | 2003-10-21 | Depomed, Inc. | Extending the duration of drug release within the stomach during the fed mode |
| WO1998055107A1 (en) | 1997-06-06 | 1998-12-10 | Depomed, Inc. | Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs |
| JP2003507430A (ja) * | 1999-08-25 | 2003-02-25 | ジーエムピー カンパニーズ，インコーポレーテッド | 哺乳動物中で酸素運搬を向上する薬剤 |
| WO2001024830A2 (en) * | 1999-10-05 | 2001-04-12 | Theramed, Inc. | Incorporation of chemical substances into cells |
| HK1050135A1 (zh) | 1999-11-02 | 2003-06-13 | Depomed, Inc. | 用於促进将药物给予胃的饭後模式药理学诱导 |
| DE60123384T2 (de) | 2000-02-04 | 2007-08-02 | DepoMed, Inc., Menlo Park | Dosierungsform des typs "hülle und kern" mit einer wirkstofffreisetzung, die sich der nullten ordnung annähert |
| US6488962B1 (en) | 2000-06-20 | 2002-12-03 | Depomed, Inc. | Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms |
| AU2001281071A1 (en) * | 2000-08-01 | 2002-02-13 | Gmp Companies, Inc. | Ammonium salts of hemoglobin allosteric effectors, and uses thereof |
| US6610702B2 (en) * | 2000-08-01 | 2003-08-26 | Gmp Oxycell, Inc. | Ammonium salts of inositol hexaphosphate, and uses thereof |
| US6451808B1 (en) | 2000-10-17 | 2002-09-17 | Depomed, Inc. | Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists |
| JP3678144B2 (ja) | 2000-12-22 | 2005-08-03 | ウシオ電機株式会社 | フィルム回路基板の周辺露光装置 |
| MXPA03011096A (es) | 2001-05-29 | 2004-12-06 | Depomed Dev Ltd | Metodo para el tratamiento de la enfermedad de reflujo gastroesofagico y la saturacion acida nocturna. |
| US20030091630A1 (en) | 2001-10-25 | 2003-05-15 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data |
| CA2409552A1 (en) | 2001-10-25 | 2003-04-25 | Depomed, Inc. | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
| TWI312285B (en) | 2001-10-25 | 2009-07-21 | Depomed Inc | Methods of treatment using a gastric retained gabapentin dosage |
| JP2005508358A (ja) | 2001-10-25 | 2005-03-31 | デポメド・インコーポレイテッド | 胃滞留型ロサルタン投与量を用いる治療方法 |
| US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
| US6682759B2 (en) | 2002-02-01 | 2004-01-27 | Depomed, Inc. | Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs |
| ES2232302B1 (es) | 2003-11-07 | 2006-08-01 | Universitat De Les Illes Balears | Myo-inositol hexafosfato para uso topico. |
| ES2288126B2 (es) | 2006-06-01 | 2009-07-06 | Universitat De Les Illes Balears | Utilizacion de fitato como agente inhibidor de la disolucion de cristales de sales calcicas para la prevencion o tratamiento de la osteoporosis. |
| ES2332636B1 (es) | 2008-08-06 | 2011-02-10 | Universitat De Les Illes Balears | Composicion de liquido de dialisis. |
| BR112014007405B1 (pt) | 2011-09-29 | 2021-07-13 | Eth Zurich | Composto, mio-inositol-pentaquisfosfato-2-peg(400) e forma farmacêutica |
| EP2579036A1 (en) | 2011-10-06 | 2013-04-10 | Laboratorios Sanifit, S.L. | Method for the direct detection and/or quantification of at least one compound with a molecular weight of at least 200 |
| ES2495666B1 (es) * | 2013-03-15 | 2015-08-10 | Laboratoris Sanifit, S.L. | Uso de derivados con enlaces c-o-p en pacientes con fallo renal |
| JP6893037B2 (ja) | 2015-12-11 | 2021-06-23 | エーテーハー・チューリッヒＥＴＨ Ｚｕｒｉｃｈ | Ｃ．ｄｉｆｆｉｃｉｌｅ感染のための４，６−ジ−（Ｏ−チオホスフェート）−イノシトール−１，２，３，５−テトラ−Ｏ−スルフェート |
| DK3386548T3 (da) * | 2015-12-11 | 2021-05-25 | Eth Zuerich | Inositol-derivater til anvendelse i patologisk krystallisering |
-
2020
- 2020-01-30 MX MX2021008966A patent/MX2021008966A/es unknown
- 2020-01-30 BR BR112021014897-3A patent/BR112021014897A2/pt unknown
- 2020-01-30 CN CN202080010978.XA patent/CN113365636A/zh active Pending
- 2020-01-30 CA CA3130735A patent/CA3130735A1/en active Pending
- 2020-01-30 EP EP20709635.5A patent/EP3917535A1/en active Pending
- 2020-01-30 WO PCT/ES2020/070070 patent/WO2020157362A1/en not_active Ceased
- 2020-01-30 AU AU2020213713A patent/AU2020213713B2/en active Active
- 2020-01-30 KR KR1020217023799A patent/KR20210148078A/ko active Pending
- 2020-01-30 JP JP2021532911A patent/JP2022521119A/ja active Pending
-
2021
- 2021-07-20 US US17/381,052 patent/US20220000889A1/en not_active Abandoned
- 2021-07-22 IL IL285084A patent/IL285084A/en unknown
-
2023
- 2023-04-11 US US18/298,811 patent/US20230248749A1/en not_active Abandoned
-
2024
- 2024-09-13 JP JP2024158993A patent/JP2024175025A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020189864A5 (enExample) | ||
| JP2022521119A5 (enExample) | ||
| JP2023500020A5 (enExample) | ||
| JP2012529483A5 (enExample) | ||
| JP2007500229A5 (enExample) | ||
| JP2020075939A5 (enExample) | ||
| US20080319038A1 (en) | Preventative or therapeutic agent for acute renal failure | |
| JP2024503723A5 (enExample) | ||
| JP2005506294A (ja) | テガフル、ウラシル、フォリン酸、パクリタキセルおよびカルボプラチンの投与による腫瘍の治療方法および剤形 | |
| CA2906196A1 (en) | Enantiomerically enriched s-oxprenolol compositions for treating cancer | |
| JP2020510043A5 (enExample) | ||
| RU2002101622A (ru) | Нафтохиноновые производные и их использование для лечения и борьбы с туберкулезом | |
| JP2025148449A5 (enExample) | ||
| TW202038932A (zh) | 使用6,8-雙-苄硫基-辛酸和自噬抑制劑治療癌症之治療方法及組成物 | |
| KR20120138229A (ko) | 정맥내 투여용 이부프로펜을 이용한 중증 환자의 치료 | |
| JPH1036365A5 (enExample) | ||
| TW202038931A (zh) | 使用6,8-雙-苄硫基-辛酸和自噬抑制劑治療癌症之治療方法及組成物 | |
| RU2021125195A (ru) | Соединения инозитолфосфата для применения для увеличения тканевой перфузии | |
| US6593329B1 (en) | Method for the treatment or prevention of coronary graft vasospasm | |
| JPH0624989A (ja) | 抗−アテローム性動脈硬化薬としてのドキサゾシンのヒドロキシル化代謝産物および誘導体 | |
| EP1203585B1 (en) | Anti-ischemic agent | |
| RU2259827C2 (ru) | Лечение или предупреждение гипотензии и шока | |
| EP0717625B1 (en) | A method of treating liver disease and like indications with vasodilating agents | |
| JP4253371B2 (ja) | 筋クランプ治療剤 | |
| JP6959049B2 (ja) | 新規低アルブミン血症改善薬 |